BioSpace News Archive

Foresight Diagnostics, a leader in molecular cancer diagnostics, announced the presentation of a study in collaboration with a leading cancer center at the upcoming annual meeting of the American Association for Cancer Research (AACR).

Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET.

Inozyme Pharma, Inc. announced the grant of an inducement award outside of the Company’s 2020 Stock Incentive Plan to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D.

Neuronetics, Inc. provided a corporate update which includes entering into a new credit facility with investment affiliates managed by SLR Capital Partners, LLC and providing Greenbrook TMS with a promissory note as part of an updated TMS device supply agreement.

Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the year ended December 31, 2022 and highlighted recent business updates.

Acasti Pharma Inc., a late-stage specialty pharma company advancing drug candidates for rare and orphan diseases, announced the appointment of Prashant Kohli as Acasti’s new Chief Executive Officer, succeeding Jan D’Alvise.

Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,464,749 to Microbion with claims to the use of Microbion’s proprietary pravibismane inhaled composition for treatment of pulmonary infections.

Avantor, Inc. announced that it will release its first quarter 2023 financial results before the market opens on Friday, April 28, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Business Officer, Neil Abdollahian, will present at the 22nd Annual Needham Healthcare Conference which will take place virtually.

AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced that it closed an additional $8.8 million in new financing, bringing its Series B round to $28.8 million total.